Mutual detection of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in blood and saliva of Cameroonians with and without Kaposi's sarcoma.
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ blood
Cameroon
Case-Control Studies
Coinfection
/ blood
Female
HIV Infections
/ blood
Herpesvirus 4, Human
/ pathogenicity
Herpesvirus 8, Human
/ pathogenicity
Humans
Male
Middle Aged
Saliva
/ virology
Sarcoma, Kaposi
/ blood
Seroepidemiologic Studies
Young Adult
Africa
EBV
IgE
KSHV
Kaposi's sarcoma
copathogens
virus shedding
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
received:
26
02
2019
revised:
24
05
2019
accepted:
14
06
2019
pubmed:
3
7
2019
medline:
25
1
2020
entrez:
3
7
2019
Statut:
ppublish
Résumé
Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) are prevalent in sub-Saharan Africa, together with HIV; the consequent burden of disease is grave. The cofactors driving transmission of the two viruses and pathogenesis of associated malignancies are not well understood. We measured KSHV and EBV DNA in whole blood and saliva as well as serum antibodies levels in 175 Cameroonians with Kaposi's sarcoma and 1,002 age- and sex-matched controls with and without HIV. KSHV seroprevalence was very high (81%) in controls, while EBV seroprevalence was 100% overall. KSHV DNA was detectable in the blood of 36-46% of cases and 6-12% of controls; EBV DNA was detected in most participants (72-89%). In saliva, more cases (50-58%) than controls (25-28%) shed KSHV, regardless of HIV infection. EBV shedding was common (75-100%); more HIV+ than HIV- controls shed EBV. Cases had higher KSHV and EBV VL in blood and saliva then controls, only among HIV+ participants. KSHV and EBV VL were also higher in HIV+ than in HIV- controls. Cases (but not controls) were more likely to have detectable KSHV in blood if they also had EBV, whereas shedding of each virus in saliva was independent. While EBV VL in saliva and blood were modestly correlated, no correlation existed for KSHV. Numerous factors, several related to parasitic coinfections, were associated with detection of either virus or with VL. These findings may help better understand the interplay between the two gammaherpesviruses and generally among copathogens contributing to cancer burden in sub-Saharan Africa.
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2468-2477Subventions
Organisme : Medical Research Council
ID : MC_UU_00027/2
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : N01-CO-12400
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : 1U01AI069927
Pays : International
Informations de copyright
© 2019 UICC.
Références
IARC. Cancer in Sub-Saharan Africa, vol. 167. Lyon, France: IARC, 2018.
Dedicoat M, Newton R. Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. Br J Cancer 2003;88:1-3.
de Sanjose S, Mbisa G, Perez-Alvarez S, et al. Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. J Infect Dis 2009;199:1449-56.
Butler LM, Dorsey G, Hladik W, et al. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. J Infect Dis 2009;200:430-8.
Wojcicki JM. Traditional behavioural practices, the exchange of saliva and HHV-8 transmission in sub-Saharan African populations. Br J Cancer 2003;89:2016-7.
Rochford R. Epidemiology of EBV. In: Damania B, Pipas JM, eds DNA tumor viruses, vol. xxvi. New York: Springer, 2009. 794.
Daud II, Coleman CB, Smith NA, et al. Breast Milk as a potential source of Epstein-Barr virus transmission among infants living in a malaria-endemic region of Kenya. J Infect Dis 2015;212:1735-42.
Stolka K, Ndom P, Hemingway-Foday J, et al. Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon. Cancer Epidemiol 2014;38:137-43.
Mbisa GL, Miley W, Gamache CJ, et al. Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. J Immunol Methods 2010;356:39-46.
Smith NA, Baresel PC, Jackson CL, et al. Differences in the Epstein-Barr virus gp350 IgA antibody response are associated with increased risk for Coinfection with a second strain of Epstein-Barr virus. J Infect Dis 2019;219:955-63.
Labo N, Miley W, Marshall V, et al. Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome. PLoS Pathog 2014;10:e1004046.
Brown EE, Whitby D, Vitale F, et al. Correlates of human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma. Int J Epidemiol 2005;34:1110-7.
Brown EE, Whitby D, Vitale F, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer 2006;107:2282-90.
Wakeham K, Johnston WT, Nalwoga A, et al. Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study. Int J Cancer 2015;136:2822-30.
Wojcicki JM, Newton R, Urban MI, et al. Risk factors for high anti-HHV-8 antibody titers (> or =1:51,200) in black, HIV-1 negative south African cancer patients: a case control study. BMC Infect Dis 2003;3:21.
Ziegler J, Newton R, Bourboulia D, et al. Risk factors for Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda. Int J Cancer 2003;103:233-40.
Mbondji-Wonje C, Ragupathy V, Lee S, et al. Seroprevalence of human herpesvirus-8 in HIV-1 infected and uninfected individuals in Cameroon. Viruses 2013;5:2253-9.
Mulu A, Kassu A, Legesse M, et al. Helminths and malaria co-infections are associated with elevated serum IgE. Parasit Vectors 2014;7:240.
Gessain A, Mauclere P, van Beveren M, et al. Human herpesvirus 8 primary infection occurs during childhood in Cameroon, Central Africa. Int J Cancer 1999;81:189-92.
Bestetti G, Renon G, Mauclere P, et al. High seroprevalence of human herpesvirus-8 in pregnant women and prostitutes from Cameroon. AIDS 1998;12:541-3.
Betsem E, Cassar O, Afonso PV, et al. Epidemiology and genetic variability of HHV-8/KSHV in pygmy and bantu populations in Cameroon. PLoS Negl Trop Dis 2014;8:e2851.
Cornejo Castro EM, Morrison BJ, Marshall VA, et al. Relationship between human leukocyte antigen alleles and risk of Kaposi's sarcoma in Cameroon. Genes Immun 2019; doi: 10.1038/s41435-019-0077-9. [Epub ahead of print].
Alkharsah KR, Dedicoat M, Blasczyk R, et al. Influence of HLA alleles on shedding of Kaposi sarcoma-associated herpesvirus in saliva in an African population. J Infect Dis 2007;195:809-16.
Guech-Ongey M, Verboom M, Pfeiffer RM, et al. HLA polymorphisms and detection of Kaposi sarcoma-associated herpesvirus DNA in saliva and peripheral blood among children and their mothers in the Uganda sickle cell anemia KSHV study. Infect Agent Cancer 2010;5:21.
Newton R, Labo N, Wakeham K, et al. Kaposi sarcoma-associated Herpesvirus in a rural Ugandan cohort, 1992-2008. J Infect Dis 2018;217:263-9.
Pellet C, Kerob D, Dupuy A, et al. Kaposi's sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic Kaposi's sarcoma. J Invest Dermatol 2006;126:621-7.
Pellet C, Chevret S, Frances C, et al. Prognostic value of quantitative Kaposi sarcoma-associated herpesvirus load in posttransplantation Kaposi sarcoma. J Infect Dis 2002;186:110-3.
Engels EA, Biggar RJ, Marshall VA, et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 2003;17:1847-51.
Wakeham K, Johnston WT, Nalwoga A, et al. Trends in Kaposi's sarcoma-associated herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study. Int J Cancer 2015;136:2822-30.
Newton R, Labo N, Wakeham K, et al. Determinants of Gammaherpesvirus shedding in saliva among Ugandan children and their mothers. J Infect Dis 2018;218:892-900.
Mbulaiteye SM, Pfeiffer RM, Engels EA, et al. Detection of kaposi sarcoma-associated herpesvirus DNA in saliva and buffy-coat samples from children with sickle cell disease in Uganda. J Infect Dis 2004;190:1382-6.
Moormann AM, Chelimo K, Sumba OP, et al. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 2005;191:1233-8.
Rochford R, Moormann AM. Burkitt's lymphoma. Curr Top Microbiol Immunol 2015;390:267-85.
Wakeham K, Webb EL, Sebina I, et al. Risk factors for seropositivity to Kaposi sarcoma-associated herpesvirus among children in Uganda. J Acquir Immune Defic Syndr 2013;63:228-33.
Wakeham K, Webb EL, Sebina I, et al. Parasite infection is associated with Kaposi's sarcoma associated herpesvirus (KSHV) in Ugandan women. Infect Agent Cancer 2011;6:15.
Whitby D, Marshall VA, Bagni RK, et al. Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. Int J Cancer 2007;120:321-8.
Nalwoga A, Cose S, Nash S, et al. Relationship between anaemia, malaria co-infection and Kaposi sarcoma-associated herpesvirus (KSHV) seropositivity in a population-based study in rural Uganda. J Infect Dis 2018;218:1061-5.
Goedert JJ. Nonsmoking and other cofactors for Kaposi's sarcoma. AIDS 2009;23:273-4.
Kahn JA, Rudy BJ, Xu J, et al. Prevalence and risk factors for oral DNA tumor viruses in HIV-infected youth. J Med Virol 2016;88:1944-52.
Newton R, Labo N, Wakeham K, et al. Determinants of gamma-herpesvirus shedding in saliva among Ugandan children and their mothers. J Infect Dis 2018;218:892-900.
Jiang Y, Xu D, Zhao Y, et al. Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. PLoS One 2008;3:e1569.
Xu D, Coleman T, Zhang J, et al. Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. J Virol 2007;81:6068-78.
McHugh D, Caduff N, Barros MHM, et al. Persistent KSHV infection increases EBV-associated tumor formation in vivo via enhanced EBV lytic gene expression. Cell Host Microbe 2017;22:61-73.e7.
Marshall VA, Labo N, Hao XP, et al. Gammaherpesvirus infection and malignant disease in rhesus macaques experimentally infected with SIV or SHIV. PLoS Pathog 2018;14:e1007130.
Nalwoga A, Cose S, Wakeham K, et al. Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. Trop Med Int Health 2015;20:665-72.
Leffler J, Stumbles PA, Strickland DH. Immunological processes driving IgE sensitisation and disease development in males and females. Int J Mol Sci 2018;19:E1554.
Small CB, McGowan JP, Klein RS, et al. Serum IgE levels in patients with human immunodeficiency virus infection. Ann Allergy Asthma Immunol 1998;81:75-80.
Maggi E, Manetti R, Annunziato F, et al. CD8+ T lymphocytes producing Th2-type cytokines (Tc2) in HIV-infected individuals. J Biol Regul Homeost Agents 1995;9:78-81.
Reese TA, Wakeman BS, Choi HS, et al. Coinfection. Helminth infection reactivates latent gamma-herpesvirus via cytokine competition at a viral promoter. Science 2014;345:573-7.